anti-PD-1 + anti-CTLA-4

Anti-PD-1 + anti-CTLA-4 refers to a combination immunotherapy strategy that simultaneously targets two distinct immune checkpoint pathways to enhance the anti-tumor immune response. Anti-PD-1 (Programmed Death receptor-1) antibodies, such as nivolumab or pembrolizumab, prevent the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, thereby reversing T-cell exhaustion. Anti-CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4) antibodies, such as ipilimumab, block the inhibitory signal during the early stages of T-cell activation in the lymph nodes. By combining these agents, the treatment promotes both the activation of new T-cell clones and the reinvigoration of existing effector T cells within the tumor microenvironment. This dual blockade has demonstrated significant efficacy in various cancers, including advanced melanoma, renal cell carcinoma, and non-small cell lung cancer, though it is associated with a higher incidence of immune-related adverse events (irAEs) compared to monotherapy.

Brand names

Opdivo + Yervoy

Other names

PD-1 inhibitor + CTLA-4 inhibitordual checkpoint blockadecombined PD-1 and CTLA-4 inhibitionanti-PD-1/anti-CTLA-4